Cargando…

Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types

Formyl peptide receptor-like 1 inhibitor protein (FLIPr) is an immune evasion protein produced by Staphylococcus aureus, and FLIPr is a potential vaccine candidate for reducing Staphylococcus aureus virulence and biofilm formation. We produced recombinant lipidated FLIPr (rLF) to increase the immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Ming-Shu, Chen, Mei-Yu, Hsu, Chia-Wei, Tsai, Yu-Wen, Chiu, Fang-Feng, Hsu, Cheng-Lung, Lin, Chang-Ling, Wu, Chiao-Chieh, Tu, Ling-Ling, Chiang, Chen-Yi, Liu, Shih-Jen, Liao, Ching-Len, Chen, Hsin-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236402/
https://www.ncbi.nlm.nih.gov/pubmed/37268688
http://dx.doi.org/10.1038/s41541-023-00680-4
_version_ 1785052911526477824
author Hsieh, Ming-Shu
Chen, Mei-Yu
Hsu, Chia-Wei
Tsai, Yu-Wen
Chiu, Fang-Feng
Hsu, Cheng-Lung
Lin, Chang-Ling
Wu, Chiao-Chieh
Tu, Ling-Ling
Chiang, Chen-Yi
Liu, Shih-Jen
Liao, Ching-Len
Chen, Hsin-Wei
author_facet Hsieh, Ming-Shu
Chen, Mei-Yu
Hsu, Chia-Wei
Tsai, Yu-Wen
Chiu, Fang-Feng
Hsu, Cheng-Lung
Lin, Chang-Ling
Wu, Chiao-Chieh
Tu, Ling-Ling
Chiang, Chen-Yi
Liu, Shih-Jen
Liao, Ching-Len
Chen, Hsin-Wei
author_sort Hsieh, Ming-Shu
collection PubMed
description Formyl peptide receptor-like 1 inhibitor protein (FLIPr) is an immune evasion protein produced by Staphylococcus aureus, and FLIPr is a potential vaccine candidate for reducing Staphylococcus aureus virulence and biofilm formation. We produced recombinant lipidated FLIPr (rLF) to increase the immunogenicity of FLIPr and showed that rLF alone elicited potent anti-FLIPr antibody responses to overcome the FLIPr-mediated inhibition of phagocytosis. In addition, rLF has potent immunostimulatory properties. We demonstrated that rLF is an effective adjuvant. When an antigen is formulated with rLF, it can induce long-lasting antigen-specific immune responses and enhance mucosal and systemic antibody responses as well as broad-spectrum T-cell responses in mice. These findings support further exploration of rLF in the clinic as an adjuvant for various vaccine types with extra benefits to abolish FLIPr-mediated immunosuppressive effects.
format Online
Article
Text
id pubmed-10236402
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102364022023-06-04 Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types Hsieh, Ming-Shu Chen, Mei-Yu Hsu, Chia-Wei Tsai, Yu-Wen Chiu, Fang-Feng Hsu, Cheng-Lung Lin, Chang-Ling Wu, Chiao-Chieh Tu, Ling-Ling Chiang, Chen-Yi Liu, Shih-Jen Liao, Ching-Len Chen, Hsin-Wei NPJ Vaccines Article Formyl peptide receptor-like 1 inhibitor protein (FLIPr) is an immune evasion protein produced by Staphylococcus aureus, and FLIPr is a potential vaccine candidate for reducing Staphylococcus aureus virulence and biofilm formation. We produced recombinant lipidated FLIPr (rLF) to increase the immunogenicity of FLIPr and showed that rLF alone elicited potent anti-FLIPr antibody responses to overcome the FLIPr-mediated inhibition of phagocytosis. In addition, rLF has potent immunostimulatory properties. We demonstrated that rLF is an effective adjuvant. When an antigen is formulated with rLF, it can induce long-lasting antigen-specific immune responses and enhance mucosal and systemic antibody responses as well as broad-spectrum T-cell responses in mice. These findings support further exploration of rLF in the clinic as an adjuvant for various vaccine types with extra benefits to abolish FLIPr-mediated immunosuppressive effects. Nature Publishing Group UK 2023-06-02 /pmc/articles/PMC10236402/ /pubmed/37268688 http://dx.doi.org/10.1038/s41541-023-00680-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hsieh, Ming-Shu
Chen, Mei-Yu
Hsu, Chia-Wei
Tsai, Yu-Wen
Chiu, Fang-Feng
Hsu, Cheng-Lung
Lin, Chang-Ling
Wu, Chiao-Chieh
Tu, Ling-Ling
Chiang, Chen-Yi
Liu, Shih-Jen
Liao, Ching-Len
Chen, Hsin-Wei
Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types
title Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types
title_full Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types
title_fullStr Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types
title_full_unstemmed Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types
title_short Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types
title_sort recombinant lipidated flipr effectively enhances mucosal and systemic immune responses for various vaccine types
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236402/
https://www.ncbi.nlm.nih.gov/pubmed/37268688
http://dx.doi.org/10.1038/s41541-023-00680-4
work_keys_str_mv AT hsiehmingshu recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT chenmeiyu recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT hsuchiawei recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT tsaiyuwen recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT chiufangfeng recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT hsuchenglung recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT linchangling recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT wuchiaochieh recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT tulingling recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT chiangchenyi recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT liushihjen recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT liaochinglen recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes
AT chenhsinwei recombinantlipidatedflipreffectivelyenhancesmucosalandsystemicimmuneresponsesforvariousvaccinetypes